Non-small cell lung cancer consultation
The National Institute for Health and Care Excellence (NICE) is consulting on its review of the use of erlotinib (Tarceva; Roche) and gefitinib (Iressa; AstraZeneca) for the treatment of non-small cell lung cancer that has progressed after prior chemotherapy. The new draft guidance provisionally recommends erlotinib as a treatment option for people with non-small-cell lung cancer that has progressed after prior chemotherapy in specific circumstances – but does not recommend gefitinib. The draft guidance is open for comment until 28 August 2014. Further information can be found on the NICE website, using the technology appraisal (TA) references TA162 and TA175.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066133
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com